Le Lézard
Classified in: Health, Business
Subjects: NPT, CSR, SRI

NCPDP Foundation Awards $100,000 to Support Real-Time Prescription Benefit (RTPB) Standard Projects at DrFirst and Johns Hopkins Medicine


SCOTTSDALE, Ariz., Dec. 2, 2019 /PRNewswire-PRWeb/ -- The NCPDP Foundation Board of Trustees, who govern the 501(c)(3) nonprofit charitable organization that is affiliated with NCPDP, has approved $100,000 in funding to support two research projects piloting the Beta version of NCPDP's Real-Time Prescription Benefit (RTPB) Standard. The pilots can result in identifying potential enhancements to the Standard, which is highly anticipated by the healthcare industry and will be finalized by August 2020.

A $50,000 grant is awarded to DrFirst for a pilot in partnership with RxSense, and another $50,000 grant is awarded to Johns Hopkins Medicine for a study in partnership with Surescripts.

NCPDP's RTPB Standard provides a standardized format for the prescriber, pharmacy and pharmacy claims processor to exchange real-time information about a patient's drug benefit coverage and out-of-pocket cost prior to prescribing and dispensing. The ability to instantly access this data at the point of prescribing provides unprecedented transparency which can increase speed to therapy and can have a positive impact on medication adherence and health outcomes.

The DrFirst project will evaluate the effectiveness of the NCPDP RTPB Standard by testing and validating the accuracy and timeliness of beneficiary information exchanged between the prescriber, pharmacy, and pharmacy claims processor at the point of care. Real-time information about an individual's prescription coverage can help clinicians discuss options with patients while they are together to improve medication adherence and reduce prescription abandonment at the pharmacy.

The Johns Hopkins Medicine research team, led by Ashwini Davison MD, Jessica Merrey PharmD, and Danny Lee, MD will be characterizing the real-world use of a RTPB tool and evaluating the impact of NCPDP's RTPB Standard on key stakeholders. They hope to provide evidence that RTPB tools have a positive effect on patients and reduce the burden on prescribers, payers, and pharmacies when new medications are prescribed.

The RTPB Standard was developed using NCPDP's multi-stakeholder, consensus-building process and is designed to conform to providers' workflows.

"We are committed to finalizing the Real-Time Prescription Benefit Standard in preparation for industry adoption and appreciate the support of the Foundation and the grantees whose research can help fortify the standard," said Lee Ann Stember, President & CEO of NCPDP.

NCPDP Foundation Chair, Mindy D. Smith, BSPharm, R.Ph., MHA, explained, "The NCPDP Foundation's funding of research that can identify potential enhancements to the Real-Time Prescription Benefit Standard contributes to making healthcare delivery better, safer and cost-effective for the patient. The Standard also benefits providers who can have better informed conversations with patients to select the best medication based on the patient's individualized needs."

About NCPDP Foundation
The NCPDP Foundation is a 501(c)(3) nonprofit charitable organization headquartered in Scottsdale, Arizona and is affiliated with the National Council for Prescription Drug Programs (NCPDP). The NCPDP Foundation was established in December 2012 to support research, education and charitable involvement within the healthcare industry. For more information, visit http://ncpdpfoundation.org.

 

SOURCE NCPDP Foundation


These press releases may also interest you

at 03:47
Zest Dental Solutions, a global leader in innovative dental solutions proudly announces a strategic partnership with The Pathway. Founded by Justin Moody, DDS and based in Arizona, The Pathway is a continuing education program that teaches dentists...

at 03:34
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease...

at 03:16
First quarter Net sales reached SEK 9.4 (13.0) million.The operating result totaled SEK -18.4 (-14.4) million.Earnings per share, basic and diluted, were SEK -0.11 (-0.09).Cash flow from operating activities totaled SEK -7.3 (-12.2) million.CEO...

at 03:03
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide its platform for medical education, Sectra Education Portal, to four university colleges in Denmark. With the solution, they aim to elevate the educational...

at 03:00
Sentrycs, a leading innovator in adaptive counter-drone solutions, is proud to announce its inclusion in the prestigious UK National Protective Security Authority Catalogue of Security Equipment (NPSA CSE).  ...

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...



News published on and distributed by: